aXichem (AXIC) Q2 2025 earnings summary

Executive summary

• Net sales for Jan–June 2025 increased to SEK 10,035 thousand from SEK 6,675 thousand year-over-year, with Q2 sales at SEK 6,648 thousand, up from SEK 5,867 thousand.

• Operating loss widened to SEK -9,274 thousand for H1 2025 (from SEK -5,418 thousand), and SEK -3,398 thousand for Q2 (from SEK -918 thousand).

• Cash and cash equivalents at June 30, 2025, were SEK 6,781 thousand, down from SEK 10,024 thousand a year earlier.

• Equity ratio remained strong at 90% (88% last year).

Financial highlights

• Earnings per share for H1 2025 were SEK -0.16 (SEK -0.21), and for Q2 SEK -0.06 (SEK -0.03).

• Equity per share at period end was SEK 1.03 (SEK 1.60).

• Investments in fixed assets for H1 2025 totaled SEK 3,205 thousand.

• Depreciation for H1 2025 was SEK 2,353 thousand.

• Cash flow from operations for H1 2025 was SEK -7,462 thousand.

Outlook and guidance

• Expects gradual increase in order intake for both animal feed and dietary supplements in coming years.

• Focus remains on commercialization of phenylcapsaicin under aXiphenⓇ and aXiviteⓇ brands.

• Ongoing regulatory processes in the EU and expansion in Brazil are prioritized.